Myocardial apoptosis (None established; sometimes abbreviated as "cardiac apoptosis" in literature, but not a standard abbreviation.)

"Myocardial apoptosis" refers to the regulated process of programmed cell death occurring within cardiac muscle cells. This phenomenon plays an important role following myocardial infarction and during heart failure progression—where excessive loss of viable cardiomyocytes through inappropriate activation of apoptotic mechanisms contributes significantly to adverse cardiac remodeling and functional decline. While inhibition or modulation of this process has been proposed as a therapeutic strategy—especially via targeting key molecules such as caspases or upstream regulators—the term itself does not denote an individual druggable protein but rather encompasses multiple molecular targets within interconnected signaling networks governing cellular survival versus programmed elimination.

Other names

Cardiac apoptosisCardiomyocyte apoptosisApoptosis in myocardium

Drugs targeting myocardial/cardiac apoptosis generally act by: Inhibiting caspases or other executioner proteins in the apoptotic cascade. Modulating signaling pathways such as PI3K/Akt, MAPK/ERK/JNK/p38 MAPK pathways. Reducing oxidative stress and inflammation that trigger apoptotic signaling. Enhancing pro-survival signals within cardiomyocytes.